Regeneron Pharmaceuticals
REGN
$611.34
-3.79%
Regeneron Pharmaceuticals is a biotechnology company that discovers, develops, and commercializes therapies for serious medical conditions, including eye diseases, cardiovascular disease, cancer, and inflammation. The company is a well-established leader in its field, distinguished by its blockbuster drugs like Eylea and Dupixent, and its strategic partnerships with major pharmaceutical players such as Sanofi and Bayer. The current investor narrative is dominated by a significant clinical setback, specifically the Phase 3 failure of a key cancer drug combination in May 2026, which has pressured the stock, alongside ongoing strategic considerations around drug pricing agreements with the U.S. government and the continued expansion of its flagship immunology franchise.…
REGN
Regeneron Pharmaceuticals
$611.34
Related headlines
Investment Opinion: Should I buy REGN Today?
Rating & Thesis: Hold. Regeneron is a high-quality company with a strong financial base caught in a transitional phase, where attractive valuation is counterbalanced by near-term negative catalysts and uncertain growth re-acceleration. The mixed analyst sentiment, with recent actions ranging from 'Buy' to 'Equal-Weight,' reflects this stalemate.
Supporting Evidence: The recommendation is supported by four key data points: 1) The compelling forward P/E of 11.69x suggests the market has priced in significant pessimism. 2) The company's exceptional gross margin of 84.95% and ROE of 14.4% confirm a profitable, well-run core business. 3) The fortress balance sheet (D/E 0.087) and strong FCF provide a margin of safety. 4) However, the severe technical breakdown (-17.26% over 3 months) and the concrete pipeline failure create a clear overhang that limits near-term upside potential.
Risks & Conditions: The two biggest risks are further pipeline disappointments beyond the recent oncology failure and accelerated margin pressure from the new drug pricing agreement. This Hold would upgrade to a Buy if the stock stabilizes above its recent lows and shows evidence that core franchise growth (e.g., Dupixent) is accelerating to offset pipeline concerns, or if the forward P/E compresses further toward 10x. It would downgrade to a Sell if revenue growth turns negative or if the stock breaks decisively below its 52-week low of $476.49. Relative to its own history and the quality of its assets, the stock appears fairly valued to slightly undervalued, but not compellingly so given the lack of a clear near-term catalyst.
Sign up to view all
REGN 12-Month Price Forecast
Regeneron presents a classic 'value trap' vs. 'fallen angel' dilemma. The fundamentals—profitability, cash flow, balance sheet—are elite and justify a higher multiple. However, the loss of a key growth driver (oncology) and maturing core revenue create a justifiable growth discount. The neutral stance reflects high uncertainty; the path of least resistance is sideways consolidation as investors await clarity on the post-setback strategy. The stance would turn bullish on evidence of successful capital allocation or pipeline progress, and bearish on a breakdown below $476 or a material guidance cut. The high cash balance is the critical differentiator that limits severe downside.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Regeneron Pharmaceuticals's 12-month outlook, with a consensus price target around $794.74 and implied upside of +30.0% versus the current price.
Average Target
$794.74
11 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
11
covering this stock
Price Range
$489 - $795
Analyst target range
With 11 analysts providing coverage, the consensus sentiment appears mixed but leans bullish, given the prevalence of 'Buy' or 'Overweight' ratings in recent institutional actions. The average EPS estimate for the coming period is $71.47, with a revenue estimate of $21.46 billion, though a specific consensus price target is not provided in the data. The target price range is also not explicitly stated, but the wide dispersion between the low EPS estimate of $64.83 and the high of $78.68 signals moderate uncertainty among analysts regarding future earnings power. Recent rating actions from firms like RBC Capital ('Sector Perform'), Guggenheim ('Buy'), and Morgan Stanley ('Equal Weight') in early 2026 show no major downgrades following the Q4 earnings, but the subsequent clinical trial failure in May 2026 may not yet be fully reflected in these older ratings.
Bulls vs Bears: REGN Investment Factors
The investment debate for Regeneron is currently dominated by a clash between its formidable financial strength and attractive valuation against a deteriorating technical picture and a significant pipeline failure. The bear side holds stronger near-term evidence, as the stock's severe price action and the concrete clinical setback are immediate and impactful, outweighing the fundamental strengths which are more defensive in nature. The single most important tension is whether the company's robust cash-generating core franchises (Eylea, Dupixent) can sustain enough growth to offset the oncology pipeline disappointment and justify a valuation re-rating, or if the growth deceleration and pipeline gaps will lead to prolonged multiple compression. The resolution of this tension hinges on upcoming commercial execution and pipeline updates.
Bullish
- Strong Financial Fortress: The company has a pristine balance sheet with a debt-to-equity ratio of just 0.087 and a current ratio of 4.13, indicating virtually no financial risk and ample liquidity. This is complemented by robust free cash flow generation of $4.08 billion TTM, providing a significant buffer for R&D and shareholder returns.
- Attractive Forward Valuation: The stock trades at a forward P/E of 11.69x, a significant discount to its trailing P/E of 17.92x, signaling the market expects earnings growth. This forward multiple is also near the lower end of the stock's historical P/E range (9.98x to 36.18x), suggesting a potential value opportunity.
- High Profitability & Cash Generation: Regeneron maintains exceptional gross margins of 84.95% and an ROE of 14.4%, demonstrating a highly profitable business model. The company's TTM free cash flow of $4.08 billion underscores its ability to convert earnings into cash efficiently.
- Analyst Confidence in Core Earnings: Despite recent setbacks, analysts project an average forward EPS of $71.47, implying significant growth from recent quarterly results. The high EPS estimate of $78.68 suggests a portion of the Street sees a path for the core immunology and eye care franchises to drive earnings.
Bearish
- Major Oncology Pipeline Setback: The Phase 3 failure of a key cancer drug combination in May 2026 is a significant clinical and strategic blow, directly pressuring the stock and raising questions about the long-term growth potential beyond its flagship products. This event triggered the recent 10.47% monthly decline and severe underperformance versus the SPY.
- Severe Technical Downtrend: The stock is in a pronounced downtrend, down 17.26% over 3 months and trading at just 77% of its 52-week range, closer to its low of $476.49 than its high of $821.11. The accelerating selling pressure, with a 1-month relative strength of -15.07% vs. SPY, indicates strong negative momentum.
- Maturing Revenue Growth: Q4 2025 revenue grew only 2.5% year-over-year, a deceleration from higher rates in prior quarters, indicating the top line is maturing. While sequential quarterly growth exists, the slowdown necessitates successful pipeline launches to re-accelerate, which is now in question.
- Earnings & Margin Volatility: Net income and margins show significant quarterly swings, with the net margin dropping from 38.9% in Q3 2025 to 21.7% in Q4 2025. This volatility complicates forecasting and may reflect dependence on one-time items or partnership economics, undermining earnings quality.
REGN Technical Analysis
The stock is in a pronounced downtrend, having declined 17.26% over the past three months and 10.47% over the past month, which starkly contrasts with its positive 29.65% gain over the past year. Currently trading at $628.73, the price sits at approximately 77% of its 52-week range, positioned closer to the 52-week low of $476.49 than the high of $821.11, suggesting the stock is in a corrective phase after a strong prior run, moving from momentum highs toward a potential value zone. Recent momentum is decisively negative and diverging from the longer-term uptrend, with the 1-month decline of 10.47% and 3-month drop of 17.26% indicating accelerating selling pressure, a signal likely triggered by the recent clinical trial failure and confirmed by the stock's severe underperformance relative to the SPY, which is down 15.07% over the past month. Key technical support is the 52-week low area near $476.49, while resistance lies at the recent highs around $821.11; a breakdown below support would signal a continuation of the bearish trend, while a recovery above resistance would require a major positive catalyst. With a beta of 0.296, the stock exhibits significantly lower volatility than the broader market, which historically provided defensive characteristics but has not insulated it from recent company-specific negative news.
Beta
0.24
0.24x market volatility
Max Drawdown
-26.1%
Largest decline past year
52-Week Range
$476-$821
Price range past year
Annual Return
+23.9%
Cumulative gain past year
| Period | REGN Return | S&P 500 |
|---|---|---|
| 1m | -14.5% | +0.2% |
| 3m | -20.8% | +9.2% |
| 6m | -15.8% | +7.5% |
| 1y | +23.9% | +23.4% |
| ytd | -21.3% | +8.4% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
REGN Fundamental Analysis
Revenue growth has been positive but modest, with Q4 2025 revenue of $3.88 billion representing a 2.5% year-over-year increase; however, examining the quarterly sequence from Q1 2025 ($3.03B) to Q4 2025 ($3.88B) shows sequential quarterly revenue growth, though the year-over-year pace has decelerated from higher rates seen in prior quarters, indicating a maturing but still growing top line. The company is highly profitable, with Q4 2025 net income of $844.6 million and a robust gross margin of 84.95%, although net margins have shown some quarterly volatility, declining from 38.9% in Q3 2025 to 21.7% in Q4 2025, which may reflect increased investment or one-time items. The balance sheet is exceptionally strong, evidenced by a very low debt-to-equity ratio of 0.087, a high current ratio of 4.13, and substantial free cash flow generation, with TTM free cash flow of $4.08 billion and an ROE of 14.4%, indicating the company generates ample internal cash to fund operations, R&D, and shareholder returns without financial strain.
Quarterly Revenue
$3.9B
2025-12
Revenue YoY Growth
+0.02%
YoY Comparison
Gross Margin
+0.84%
Latest Quarter
Free Cash Flow
$4.1B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is REGN Overvalued?
Given the positive net income, the primary valuation metric is the P/E ratio. The trailing P/E is 17.92x, while the forward P/E is significantly lower at 11.69x, indicating the market expects meaningful earnings growth in the coming year. Compared to sector averages, Regeneron's trailing P/E of 17.92x and forward P/E of 11.69x are not directly comparable without a provided industry average, but the forward discount suggests the market has priced in a more conservative outlook. Historically, the current trailing P/E of 17.92x is below the stock's own historical range seen in recent quarters, which has fluctuated between approximately 9.98x and 36.18x over the past few years, positioning the current valuation near the lower end of its historical band and potentially reflecting a value opportunity if the fundamental growth story remains intact.
PE
17.9x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 5x~36x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
13.8x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: The primary financial risk is not solvency—given the near-zero debt and $4.08B in TTM FCF—but earnings volatility and growth sustainability. Net margin plunged from 38.9% to 21.7% between Q3 and Q4 2025, indicating potential lumpiness in profitability. Revenue growth has decelerated to 2.5% YoY in Q4 2025, raising concerns about dependence on a few mature blockbusters. While the balance sheet is a fortress, the company must now deploy its cash effectively to reignite growth through R&D or business development following the pipeline failure.
Market & Competitive Risks: The stock faces significant valuation compression risk, as its forward P/E of 11.69x, while low historically, could contract further if growth expectations diminish. The recent clinical failure exposes competitive risks in oncology, a critical future growth avenue. Furthermore, the drug pricing deal with the U.S. government, while mitigating regulatory uncertainty, introduces a direct long-term margin headwind. The stock's low beta of 0.296 offers little protection against these company-specific issues, as evidenced by its severe underperformance (-15.07% vs. SPY over 1 month) driven solely by internal news.
Worst-Case Scenario: The worst-case scenario involves a continuation of the current negative momentum, where the oncology pipeline setback triggers a loss of investor confidence in management's R&D prowess, leading to multiple derating. Concurrently, slower-than-expected growth from Dupixent and Eylea, combined with the financial impact of the new pricing agreement, could cause earnings estimates to be revised downward significantly. This could drive the stock to retest its 52-week low of $476.49, representing a downside of approximately -24% from the current price of $628.73. A break below that level could see a fall toward the $450 area, implying a total loss potential of -28% to -30%.
FAQ
The key risks are, in order of severity: 1) Pipeline & Growth Risk: The Phase 3 oncology failure in May 2026 damages future growth prospects, and core revenue growth is decelerating (2.5% YoY). 2) Regulatory & Pricing Risk: The new deal with the U.S. government to cut drug prices introduces a direct, long-term margin headwind. 3) Sentiment & Technical Risk: The stock is in a severe downtrend (-17.26% over 3 months) and breaking below key support could trigger further selling. 4) Earnings Volatility Risk: Net margins have shown high quarterly volatility, dropping from 38.9% to 21.7% between recent quarters, complicating forecasts.
Our 12-month forecast outlines three scenarios with associated probabilities. The Base Case (60% probability) sees the stock trading between $600 and $700 as it consolidates, supported by analyst EPS estimates of ~$71.47 but capped by growth concerns. The Bull Case (25% probability) targets $750 to $821 if core franchises outperform and sentiment improves. The Bear Case (15% probability) risks a retest of the 52-week low near $476 if earnings disappoint or sentiment worsens. The most likely outcome is the Base Case, which assumes the company executes steadily on its core business but fails to reignite a compelling growth narrative in the near term.
REGN appears fairly valued to slightly undervalued based on its forward earnings potential. The forward P/E of 11.69x represents a significant discount to its trailing P/E of 17.92x and sits near the lower end of its own historical range of approximately 9.98x to 36.18x. This discount reflects the market's lowered growth expectations following the pipeline failure. Compared to simply its financial strength (84.95% gross margin, 0.087 D/E ratio), the valuation seems cheap. However, relative to its decelerating revenue growth (2.5% YoY in Q4 2025), the multiple may be appropriate. The market is pricing in a stable, cash-generative company, not a high-growth biotech.
REGN is a good buy for patient, value-oriented investors who can tolerate near-term uncertainty, but not for those seeking near-term catalysts or pure growth. The stock trades at a compelling forward P/E of 11.69x, supported by a fortress balance sheet and strong cash flow. However, the recent 17.26% 3-month decline driven by a Phase 3 pipeline failure creates a significant overhang. The key is whether you believe the market has over-penalized the company for this setback. For long-term holders, the current price may offer an attractive entry point into a quality business, but be prepared for potential further volatility.
REGN is far more suitable for a long-term investment horizon (3+ years) than for short-term trading. The company's low beta (0.296) and lack of a near-term positive catalyst make it unlikely to see explosive short-term gains. As a long-term holding, investors can benefit from the company's durable competitive moats in immunology and ophthalmology, its immense financial flexibility to invest in the business or return capital, and a potential valuation recovery if pipeline efforts eventually bear fruit. The recent sell-off has created a more attractive long-term entry point, but investors must be patient. A short-term trader would be challenged by the stock's current lack of positive momentum and clear catalysts.